Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma

Drugs

Volumn 77, Issue 4, 2017, Pages 435-445

  Scott, Lesley J ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; PLACEBO; ANTIBODY CONJUGATE;

ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CONSOLIDATION CHEMOTHERAPY; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FOLLOW UP; HUMAN; MOTOR NEUROPATHY; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SALVAGE THERAPY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; DRUG TOLERANCE; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN;

ANTIGENS, CD30; DRUG TOLERANCE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, NON-HODGKIN; SALVAGE THERAPY;

EID: 85012235737     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0705-5     Document Type: Article

References (39)

1. Eichenauer DA, Engert A, André M, et al. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):vi70–5.
2. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2014: Hodgkin lymphoma. 2014. http://www.nccn.org/. Accessed 24 Nov 2016.
3. Siddiqi T, Thomas SH, Chen R. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmacogenom Pers Med. 2014;7:79–85.
4. Deng C, Pan B, O’Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22–7.
5. Montanari F, Diefenbach C. Relapsed Hodgkin lymphoma: management strategies. Curr Hematol Malig Rep. 2014;9(3):284–93.
6. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7.
7. Domingo-Domenech E, Comai A, Sureda A. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma. Eur Oncol Haematol. 2015;11(1):21–4.
8. Engert A. CD30-positive malignant melanomas: time for a change of management? Haematologia (Budap). 2013;98(8):1165–8.
9. Jagadeesh D, Smith MR. Antibody drug conjugates: changing the treatment landscape of lymphoma. Curr Treat Options Oncol. 2016;17:55.
10. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65.
11. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888–97.
12. European Medicines Agency. ADCETRIS 50 mg powder for concentrate for solution: summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 11 Oct 2016.
13. Garnock-Jones KP. Brentuximab vedotin: a review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs. 2013;73(4):371–81.
14. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumour activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70.
15. Kim KM, McDonagh CF, Westendorf L, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Res. 2008;7(8):2486–97.
16. Fromm JR, McEarchern JA, Kennedy D, et al. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk. 2012;12(4):280–3.
17. Gardai SJ, Heiser R, Cao A, et al. Immune systems engagement results in non-classical antibody-drug conjugate antitumor activity of brentuximab vedotin [abstract no. P099]. Haematologica. 2016;101(Suppl 5):53.
18. Han TH, Chen R, Advani R, et al. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemother Pharmacol. 2013;72(1):241–9.
19. ® (brentuximab vedotin) for injection: US prescribing information. 2016. http://www.seattlegenetics.com/. Accessed 11 Oct 2016.
20. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.
21. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant melanoma. J Clin Oncol. 2007;25(5):579–86.
22. Sweetenham J, Walewski J, Nademanee AP, et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse [abstract]. Blood. 2015;126(23):3172.
23. Ramsey SD, Nademanee A, Masszi T, et al. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016;175(5):860–7.
24. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.
25. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.
26. Ogura M, Tobinai K, Hatake K, et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840–6.
27. Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–40.
28. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–43.
29. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–6.
30. Perrot A, Monjanel H, Bouabdallah R, et al. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101(4):466–73.
31. Bröckelmann PJ, Zagadailov EA, Corman S, et al. Brentuximab vedotin in patients who are ineligible for autologous stem cell transplant with relapsed or refractory Hodgkin lymphoma: a United Kingdom and Germany retrospective study [abstract no. P093]. Haematologica. 2016;101(Suppl 5):50–1.
32. Zagadailov EA, Corman S, Hagan M, et al. Real-world effectiveness of brentuximab vedotin (BV) vs other treatments in patients with relapsed/refractory Hodgkin lymphoma (RRHL) post autologous stem-cell transplantation (ASCT) [abstract no. P094]. Haematologica. 2016;101(Suppl 5):51.
33. Salihoglu A, Elverdi T, Karadogan I, et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2015;94:415–20.
34. Yang Q-M, Hong JY, Ko YH, et al. Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. OncoTargets Ther. 2014;7:1717–22.
35. Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a Named Patient Program at four Italian centers. Oncologist. 2015;20(3):323–8.
36. Zinzani PL, Pellegrini C, Cantonetti M, et al. Brentuximab vedotin in transplant-naïve relapsed/refractory Hodgkin lymphoma: experience in 30 patients. Oncologist. 2015;20(12):1413–6.
37. Viviani S, Guidetti A, Dalto S, et al. Brentuximab vedotin (BV) an effective treatment for transplant ineligible patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) [abstract no. E1142]. Haematologica. 2015;100(Suppl 1):455–6.
38. Fanale MA, Whiting NC, Neylon E, et al. Treatment strategies to optimize outcomes with brentuximab vedotin: management of common and rare toxicities. J Target Ther Cancer. 2015;April:36–45.
39. Gopal AK, Bartlett NL, Forero-Torres A, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55:2328–34.